Premium
The prognostic significance of myelonecrosis after induction therapy in acute leukemia
Author(s) -
Cassileth Peter A.,
Brooks John S. J.
Publication year - 1987
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19871115)60:10<2363::aid-cncr2820601002>3.0.co;2-5
Subject(s) - medicine , induction therapy , acute leukemia , leukemia , clinical significance , complete remission , bone marrow , surgery , oncology , chemotherapy
Myelonecrosis is a rare antemortem finding in acute leukemia and its clinical significance is uncertain. The clinical events in nine patients with acute leukemia whose bone marrow biopsies after induction therapy revealed myelonecrosis were reviewed. No patient gained a complete remission and four patients achieved a partial remission. The median duration of survival was 2 months (range, <1 month to 8.5 months) from the start of therapy. Myelonecrosis after induction therapy in acute leukemia indicates a very poor prognosis.